Topic
Chloroquine Phosphate
About: Chloroquine Phosphate is a research topic. Over the lifetime, 268 publications have been published within this topic receiving 8471 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: It is proposed that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients.
Abstract: Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first broke out in 2019 and subsequently spread worldwide. Chloroquine has been sporadically used in treating SARS-CoV-2 infection. Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions. We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late phase in critically ill patients with SARS-CoV-2. Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection. Methods The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2-infected Vero cells. Physiologically based pharmacokinetic (PBPK) models were implemented for both drugs separately by integrating their in vitro data. Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen while considering the drug's safety profile. Results Hydroxychloroquine (EC50 = 0.72 μM) was found to be more potent than chloroquine (EC50 = 5.47 μM) in vitro. Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached 3 times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance. Conclusions Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.
2,156 citations
••
TL;DR: Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China.
Abstract: The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is shown to have apparent efficacy and acceptable safety against COVID-19 associated pneumonia in multicenter clinical trials conducted in China. The drug is recommended to be included in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19 issued by the National Health Commission of the People's Republic of China for treatment of COVID-19 infection in larger populations in the future.
2,154 citations
••
TL;DR: Chloroquine, an old antimalarial drug, may be considered for immediate use in the prevention and treatment of SARS-CoV infections.
564 citations
••
TL;DR: Results indicate that chloroquine inhibits tritiated thymidine in a dose-dependent way by interfering with the accessory function of monocytes, and that chlorquine inhibits the generation of immunoglobulin-secreting cells by selectively interfering withThe secretion of Interleukin 1 by monocytes.
149 citations
••
TL;DR: It is indicated that chloroquine is losing its efficacy against P. vivax in Myanmar.
Abstract: Fifty patients with Plasmodium vivax infection were treated with the standard regimen of chloroquine phosphate (1500 mg over 3 d) followed by primaquine (45 mg immediately and then weekly for 8 weeks); 43 patients had sensitive infections but recrudescences of parasitaemia occurred between days 3 and 14 with RI, RII and RIII patterns in one, 3 and 3 patients, respectively. All the chloroquine-resistant cases were again treated with chloroquine (1500 mg) and no further recrudescence or relapse was detected on days 21 and 28. This study indicates that chloroquine is losing its efficacy against P. vivax in Myanmar.
147 citations